Руководство по Spyre Therapeutics Inc (SYRE)
SPyre Therapeutics Inc (SYRE) достигает 52-недельного максимума 108,16 долларов США, marking a significant milestone for biotech компания. Акции обеспечили 517% возвращение за последний год и 219% прирост за год к настоящему моменту, принадлежащий рыночной капитализации в 9,5 миллиарда долларов США.
Биотехнологическая компания conducting phase 2 trial для уязвимого к колитам препарата SPY002 yielded positive results, with a statistically significant improvement в Robart's Histopathology Index score at week 12. Аналитики reacted to these developments, with Mizuho raising its price target to 120 долларов США и Deutsche Bank increasing its target to 115 долларов США, citing promising clinical remission rates.
However, not all analysts are bullish on Spyre Therapeutics. Wolfe Research has downgraded the stock rating to Peerperform, expressing concerns over valuation and potential third-quarter catalysts. Additionally, significant insider selling has occurred, with Fairmount Healthcare Fund II L.P. selling over 4,6 миллиона shares valued at approximately 399,7 миллиона долларов США.
The latest 52-week high marks a pivotal point for Spyre Therapeutics, highlighting its robust performance in the stock market. Investors seeking deeper insights can access InvestingPro's comprehensive analysis, including 14 additional ProTips and detailed financial health scores.